Ginsenoside Rh2 inhibiting HCT116 colon cancer cell proliferation through blocking PDZ-binding kinase/T-LAK cell-originated protein kinase

Journal of Ginseng Research

Volumn 40, Issue 4, 2016, Pages 400-408

  Yang, Jianjun ^a   Yuan, Donghong ^a   Xing, Tongchao ^b   Su, Hongli ^c   Zhang, Shengjun ^c   Wen, Jiansheng ^d   Bai, Qiqiang ^c   Dang, Dongmei ^a  

^a YAN'AN UNIVERSITY   (China)

^b The Fourth People s Hospital   (China)

^c Department of Anesthesiology Yanan University Affiliated Hospital   (China)

^d The Central Hospital of Tongchuan Mining Bureau   (China)

Author keywords

Antitumor effect; Apoptosis; Ginsenoside Rh2; HCT116 colorectal cancer cells; PDZ binding kinase T LAK cell originated protein kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR; GINSENOSIDE RH 2; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHOTRANSFERASE; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; ENZYME PHOSPHORYLATION; EX VIVO STUDY; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; MTS ASSAY; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84971664104     PISSN: 12268453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgr.2016.03.007     Document Type: Article

References (41)

1. Abe Y, Matsumoto S, Kito K, Ueda N. Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J Biol Chem 2000;275:21525-31.
2. Gaudet S, Branton D, Lue RA. Characterization of PDZ-binding kinase, a mitotic kinase. Proc Natl Acad Sci U S A 2000;97:5167-72.
3. Matsumoto S, Abe Y, Fujibuchi T, Takeuchi T, Kito K, Ueda N, Shigemoto K, Gyo K. Characterization of a MAPKK-like protein kinase TOPK. Biochem Bio-phys Res Commun 2004;325:997-1004.
4. Ayllón V, O’Connor R. PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response. Oncogene 2007;26:3451-61.
5. Oh SM, Zhu F, Cho YY, Lee KW, Kang BS, Kim HG, Zykova T, Bode AM, Dong Z. T-lymphokine-activated killer cell-originated protein kinase functions as a positive regulator of c-Jun-NH2-kinase 1 signaling and H-Ras-induced cell transformation. Cancer Res 2007;67:5186-94.
6. Kang NJ, Lee KW, Kim BH, Bode AM, Lee HJ, Heo YS, Boardman L, Limburg P, Lee HJ, Dong Z. Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPK. Carcinogenesis 2011;32:921-8.
7. Li S, Zhu F, Zykova T, Kim MO, Cho YY, Bode AM, Peng C, Ma W, Carper A, Langfald A, et al. T-LAK cell-originated protein kinase (TOPK) phosphorylation of MKP1 protein prevents solar ultraviolet light-induced inflammation through inhibition of the p38 protein signaling pathway. J Biol Chem 2011;286:29601-9.
8. Park JH, Nishidate T, Nakamura Y, Katagiri T. Critical roles of T-LAK cell-originated protein kinase in cytokinesis. Cancer Sci 2010;101:403-11.
9. Simons-Evelyn M, Bailey-Dell K, Toretsky JA, Ross DD, Fenton R, Kalvakolanu D, Rapoport AP. PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt’s lymphoma and other highly proliferative malignant cells. Blood Cells Mol Dis 2001;27:825-9.
10. Park JH, Jeong YJ, Won HK, Choi SY, Park JH, Oh SM. Activation of TOPK by lipopolysaccharide promotes induction of inducible nitric oxide synthase through NF-kB activity in leukemia cells. Cell Signal 2014;26:849-56.
11. Wei DC, Yeh YC, Hung JJ, Chou TY, Wu YC, Lu PJ, Cheng HC, Hsu YL, Kuo YL, Chen KY, et al. Overexpression of T-LAK cell-originated protein kinase predicts poor prognosis in patients with stage I lung adenocarcinoma. Cancer Sci 2012;103:731-8.
12. Park JH, Lin ML, Nishidate T, Nakamura Y, Katagiri T. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 2006;66:9186-95.
13. Joel M, Mughal AA, Grieg Z, Murrell W, Palmero S, Mikkelsen B, Fjerdingstad HB, Sandberg CJ, Behnan J, Glover JC, et al. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo. Mol Cancer 2015;14:121.
14. Zhu F, Zykova TA, Kang BS, Wang Z, Ebeling MC, Abe Y, Ma WY, Bode AM, Dong Z. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology 2007;133: 219-31.
15. Hu F, Gartenhaus RB, Eichberg D, Liu Z, Fang HB, Rapoport AP. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21. Oncogene 2010;29:5464-74.
16. Kim DJ, Li Y, Reddy K, Lee MH, Kim MO, Cho YY, Lee SY, Kim JE, Bode AM, Dong Z. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. Cancer Res 2012;72:3060-8.
17. Matsuo Y, Park JH, Miyamoto T, Yamamoto S, Hisada S, Alachkar H, Nakamura Y. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med 2014;259:251-9.
18. Liu Z, Li Y, Li X, Ruan CC, Wang LJ, Sun GZ. The effects of dynamic changes of malonyl ginsenosides on evaluation and quality control of Panax ginseng C.A. Meyer. J Pharm Biomed Anal 2012;64-65:56-63.
19. Hwang JT, Kim SH, Lee MS, Kim SH, Yang HJ, Kim MJ, Kim HS, Ha J, Kim MS, Kwon DY. Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyte. Biochem Biophys Res Commun 2007;364:1002-8.
20. Jiang Z, Wang Y, Zhang X, Peng T, Lu Y, Leng J, Xie Q. Preventive and therapeutic effects of ginsenoside Rb1 for neural injury during cerebral infarction in rats. Am J Chin Med 2013;41:341-52.
21. Jovanovski E, Bateman EA, Bhardwaj J, Fairgrieve C, Mucalo I, Jenkins AL, Vuksan V. Effect of Rg3-enriched Korean Red Ginseng (Panax ginseng) on arterial stiffness and blood pressure in healthy individuals: a randomized controlled trial. J Am Soc Hypertens 2014;8:537-41.
22. Oh SJ, Lee S, Choi WY, Lim CJ. Skin anti-photoaging properties of ginsenoside Rh2 epimers in UV-B-irradiated human keratinocyte cells. J Biosci 2014;39: 673-82.
23. Tang XP, Tang GD, Fang CY, Liang ZH, Zhang LY. Effects of ginsenoside Rh2 on growth and migration of pancreatic cancer cells. World J Gastroenterol 2013;19:1582-92.
24. Chung KS, Cho SH, Shin JS, Kim DH, Choi JH, Choi SY, Rhee YK, Hong HD, Lee KT. Ginsenoside Rh2 induces cell cycle arrest and differentiation in human leukemia cells by upregulating TGF-b expression. Carcinogenesis 2013;34: 331-40.
25. Zhang Q, Hong B, Wu S, Niu T. Inhibition of prostatic cancer growth by gin-senoside Rh2. Tumour Biol 2015;36:2377-81.
26. Liu S, Chen M, Li P, Wu Y, Chang C, Qiu Y, Cao L, Liu Z, Jia C. Ginsenoside Rh2 inhibits cancer stem-like cells in skin squamous cell carcinoma. Cell Physiol Biochem 2015;36:499-508.
27. Li S, Gao Y, Ma W, Guo W, Zhou G, Cheng T, Liu Y. EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2. Tumour Biol 2014;35: 5593-8.
28. Bae EA, Han MJ, Kim EJ, Kim DH. Transformation of ginseng saponins to ginsenoside Rh2 by acids and human intestinal bacteria and biological activities of their transformants. Arch Pharm Res 2004;27:61-7.
29. Zhang C, Yu H, Hou J. Effects of 20(S)-ginsenoside Rh2 and 20(R)-ginsenoside Rh2 on proliferation and apoptosis of human lung adenocarcinoma A549 cells. Zhongguo Zhong Yao Za Zhi 2011;36:1670-4.
30. Liu J, Shimizu K, Yu H, Zhang C, Jin F, Kondo R. Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cells. Fitoterapia 2010;81:902-5.
31. Zheng Y, Nan H, Hao M, Song C, Zhou Y, Gao Y. Antiproliferative effects of protopanaxadiol ginsenosides on human colorectal cancer cells. Biomed Rep 2013;4:555-8.
32. Xia X, Jiang B, Liu W, Wang P, Mou Y, Liu Y, Zhao Y, Bi X. Anti-tumor activity of three novel derivatives of ginsenoside on colorectal cancer cells. Steroids 2014;80:24-9.
33. Prigent C, Dimitrov S. Phosphorylation of serine 10 in histone H3, what for? J Cell Sci 2003;116:3677-85.
34. Wargovich MJ. Colon cancer chemoprevention with ginseng and other botanicals. J Korean Med Sci 2001;16:S81-6.
35. Cui X, Jin Y, Poudyal D, Chumanevich AA, Davis T, Windust A, Hofseth A, Wu W, Habiger J, Pena E, et al. Mechanistic insight into the ability of American ginseng to suppress colon cancer associated with colitis. Carcinogenesis 2010;31:1734-41.
36. Li B, Wang CZ, He TC, Yuan CS, Du W. Antioxidants potentiate American ginseng-induced killing of colorectal cancer cells. Cancer Lett 2010;289:62-70.
37. Wang CZ, Zhang Z, Anderson S, Yuan CS. Natural products and chemotherapeutic agents on cancer: prevention vs. treatment. Am J Chin Med 2014;42: 1555-8.
38. Yuan HD, Quan HY, Zhang Y, Kim SH, Chung SH. 20(S)-Ginsenoside Rg3 induced apoptosis in HT-29 colon cancer cells is associated with AMPK signaling pathway. Mol Med Rep 2010;3:825-31.
39. Lee SY, Kim GT, Roh SH, Song JS, Kim HJ, Hong SS, Kwon SW, Park JH. Proteome changes related to the anti-cancer activity of HT29 cells by the treatment of ginsenoside Rd. Pharmazie 2009;64:242-7.
40. King ML, Murphy LL. Role of cyclin inhibitor protein p21 in the inhibition of HCT116 human colon cancer cell proliferation by American ginseng (Panax quinquefolius) and its constituents. Phytomedicine 2010;17:261-8.
41. Li B, Zhao J, Wang CZ, Searle J, He TC, Yuan CS, Du W. Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett 2011;301:185-92.